W. Ken Fang

W. Ken Fang, PhD, currently serves as Chief Innovation Officer at Cloudbreak Pharma, a clinical stage ophthalmic drug company, since September 2020. Previously, W. Ken Fang worked as a Medicinal Chemistry Consultant at 1910 Genetics, a startup focused on drug discovery using computation and machine learning. From December 2017 to August 2019, W. Ken Fang held the position of Principal Medicinal Chemist and Head of Chemistry at Nivien Therapeutics, where responsibilities included designing small molecule kinase inhibitors for cancer treatment. W. Ken Fang's extensive experience at Allergan, Inc., spanned over 17 years in various roles, culminating as Principal Scientist, contributing significantly to drug development for neurological, ocular, and inflammatory disorders. Educational qualifications include a PhD in Organic Chemistry from the University of Michigan, a Postdoctoral Fellowship in Organic Chemistry from Penn State University, a Master's in Polymer Chemistry, and a Bachelor's in Organic Chemistry, both from Nankai University.